CurrentCignaPolicy N/A

Multiple Sclerosis (Oral -Fumarate) -Vumerity Prior Authorization Policy

Prior authorization policy for Vumerity (diroximel fumarate delayed-release capsules) for treatment of relapsing forms of multiple sclerosis under Cigna-administered benefit plans, including initial and continuation approval criteria, exclusions (non-covered uses), and requirement for specialist prescribing or consultation.

Policy Summary

PayerCigna

PolicyMultiple Sclerosis (Oral -Fumarate) -Vumerity Prior Authorization Policy

Policy CodePolicy N/A

Change TypeName and appendix updates (no criteria changes)

Effective DateJul 23, 2025

Next Review Date

Key ActionPrior authorization is required; approvals are provided for 1 year when criteria are met and the medication must be prescribed by or in consultation with a neurologist or MS specialist.

SourceLink

POLICY UPDATE CHANGES

Policy name changed to add 'Oral - Fumarate' and Appendix updates (removal/addition of agents) reflected in history.

1 yearApproval Duration (initial/continuation)

Relapsing formsCovered Indications

Concurrent DMTsNot Covered - Combination Use

Primary progressive MSNot Covered - Non-relapsing Forms

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.